|
Originally published In Press as doi:10.1074/jbc.M003915200 on August 10, 2000
J. Biol. Chem., Vol. 275, Issue 44, 34365-34374, November 3, 2000
The Homeodomain Transcription Factor Xvent-2 Mediates
Autocatalytic Regulation of BMP-4 Expression in Xenopus
Embryos*
Annette
Schuler-Metz ,
Sigrun
Knöchel ,
Eckhard
Kaufmann, and
Walter
Knöchel§
From the Abteilung Biochemie, Universität Ulm,
Albert-Einstein-Allee 11, D-89081 Ulm, Germany
Received for publication, May 9, 2000, and in revised form, July 3, 2000
 |
ABSTRACT |
Like other genes of the transforming growth
factor- family, the BMP-4 gene is regulated by an
autocatalytic loop. In Xenopus embryos this loop can be
ectopically induced by injection of BMP-2 RNA. However, cycloheximide
treatment subsequent to BMP-2 overexpression revealed that BMP
signaling is not direct but requires additional factor(s). As putative
mediator we have identified Xvent-2 which is activated by BMP-2/4
signaling and, in turn, activates BMP-4 transcription.
Using promoter/reporter assays we have delineated Xvent-2 responsive
elements within the BMP-4 gene. We further demonstrate that
Xvent-2 which has recently been characterized as a transcriptional
repressor can also act, context dependent, as an activator binding two
copies of a 5'-CTAATT-3' motif in the second intron of the
BMP-4 gene. Replacement of Xvent-2 target sites within the
goosecoid (gsc) promoter by the
BMP-4 enhancer converts Xvent-2 caused repression of
gsc to strong activation. This switch is obviously due to
adjacent nucleotides probably binding a transcriptional co-activator
interacting with Xvent-2. A model is presented describing the mechanism
of BMP-4 gene activation in Xenopus embryos at
the early gastrula stage.
 |
INTRODUCTION |
Induction and patterning of germ layers in vertebrate
embryogenesis depends on intercellular signaling and intracellular
signal transduction pathways triggered by various growth factors or
growth factor-like molecules. Investigations performed with
Xenopus laevis embryos have shown that bone morphogenetic
protein 4 (BMP-4),1 a member
of the transforming growth factor- superfamily, is a key
signal for ventralizing the mesoderm, for the inhibition of dorsalizing
and neuralizing factors and for converting ectodermal to epidermal cell
fate (1, 2). Thus it is evident that the activation of the
BMP-4 gene at the ventral side of late blastula/early gastrula stage in Xenopus embryos is of general importance
for dorso/ventral pattern formation. However, the molecular nature of
factors being responsible for the zygotic activation of this gene
in vivo is still not clear. Even in the case of invertebrate homologues, like the Drosophila gene
decapentaplegic (dpp), the mechanism governing
the initial activation at blastoderm stage is not completely
understood. It could be shown that the second intron contains
elements which contribute to the correct spatial blastoderm pattern
(3-5). A gradient of the protein dorsal, the homologue of c-Rel
in vertebrates, suppresses dpp in the ventral half, but the
factors involved in transcriptional activation of dpp in the
dorsal half remain to be elucidated. Subsequent expression of dpp in
visceral mesoderm is regulated by ultrabithorax (ubx) which itself is
up-regulated by dpp (6, 7) and, at dorsal closure, the dpp target Fos
(FosD) cooperates with Jun (JunD) by regulating the expression
of dpp (8).
Autoregulatory loops have also been reported for transforming growth
factor- (9) and Xenopus BMP-4 (10). While autoinduction of transforming growth factor- involves activatory protein 1, it is
unknown, whether the autoregulatory loop of BMP-4 is direct or requires
additional factors. We here show that the activation of the
Xenopus BMP-4 gene depends upon BMP signaling, but this activation is not observed in the presence of cycloheximide,
i.e. in the absence of protein synthesis. In search of
putative mediators we have analyzed the role of transcription factors
activated in ventral mesoderm, like the homeodomain proteins Xvent-1
(closely related to Xvent-1B and PV.1) (11-13), Xvent-2 (identical or
closely related to Vox, Xom, Xbr, and Xvent-2B) (12, 14-17), and the zinc finger factor GATA-2 (18, 19). While all these genes are known to
be activated by ectopic expression of BMP-4, only Xvent-2 up-regulates
BMP-4 transcription in vivo, and hence is a
candidate to function within the autocatalytic loop.
Deletion mutant/reporter gene assays of the Xenopus BMP-4
gene (20, 21) have shown that enhancer elements located within the
second intron and the 5'-flanking region contribute to transcriptional activation by BMP signaling. We now have further delineated these regions and demonstrate by co-injection experiments that the same regions which respond to BMP signaling are activated by Xvent-2. The
direct interaction of Xvent-2 with a corresponding target site within
the second intron was demonstrated by mobility shift and DNase I
footprint experiments. In contrast to the previous characterization of
Xvent-2 as a transcriptional repressor (22-24) we here document that
this factor can additionally work as a transcriptional activator. This
dual activity is context dependent and obviously requires a
co-activator interacting with Xvent-2 and binding to an adjacent target
site. The results suggest a model, in which the autoregulatory loop of
BMP-4 is triggered by maternal BMP-2 activating Xvent-2 and is
subsequently maintained by BMP-4 via Xvent-2 as a mediator. It is
consistent with the observation that Xvent-2 and BMP-4 show identical
spatial expression patterns throughout embryogenesis (14, 25).
 |
EXPERIMENTAL PROCEDURES |
Preparation of Deletion Mutants--
All deletion mutants were
synthesized as described previously (20) by PCR using DNA of phage
XB as template. To facilitate the directed cloning into the
luciferase pGL3 basic vector (Promega), the forward primers were 5'
elongated with a restriction site for BamHI (upstream) or
KpnI (intron) and all reverse primers with one for
HindIII (upstream) or SmaI (intron). Indicated
numbers for all mutants refer to the BMP-4 gene sequence
(EMBL AC: AJ005076). Goosecoid promoter DNA fragments were
amplified from genomic DNA by using primers which were either
KpnI or XhoI elongated (forward) and either
XhoI or HindIII elongated (reverse). Forward
226: 5'-GGGGTACCCATTAATCAGATTAACGGTGAGC-3'; forward 103:
5'-CCGCTCGAGGATGAGTCTCCTCTCACCCC-3'; reverse +3:
5'-CCCAAGCTTGTCCTCTCCCATCTGTGCCTC-3'; reverse 128: 5'-CCGCTCGAGCAAACTAATCCACTCCATTAGG-3'. Fragments were subcloned either directly or as cassettes in combination with corresponding fragments of the BMP-4 gene in pGL3.
Preparation of RNAs--
RNA used for microinjection experiments
was transcribed in vitro with SP6 or T3 polymerase in the
presence of GpppG (Cap Scribe Kit, Roche Molecular Biochemicals) using
the following templates: BMP-2 in pSP64T, EcoRI linearized,
SP6 for sense RNA; BMP-4 in pSP64T, BamHI linearized, SP6;
Xvent-2 in pSP64T, EcoRI linearized, SP6; Xvent-1 in pSP64T,
BamHI linearized, SP6; Chordin in pRN, NotI
linearized, T3; Xvent-2 (P40) in pRN, PstI linearized, T3. Capped RNAs were purified using RNeasy columns (Qiagen). The
GAL4-AD/Xvent-2 construct was generated by PCR amplification of the
GAL4 activation domain of pGAD424 (CLONTECH)
(forward primer: 5'-GGCCTCGAGATGGATAAAGCGGAATTAATTCCC-3'; reverse primer:
5'-CCGTCTAGACTACTCTTTTTTTGGGTTTGGTGGGGT-3'; synthetic stop codon underlined) which was inserted into XhoI and
XbaI sites 3' in-frame to Xvent-2 coding sequence in pCS2.
The natural stop codon had been replaced by a XhoI
restriction site. RNA was synthesized from NotI-linearized
template by SP6 polymerase.
Whole Mount in Situ Hybridization--
RNA probes were
synthesized from cDNA templates using the DIG labeling kit (Roche
Molecular Biochemicals). Whole mount in situ
hybridizations were performed with staged embryos as described (26) with slight modifications. Embryos where fixed in MEMPFA after
staining, bleached in H2O2/methanol, and
documented with a DP10 digital camera (Olympus).
Embryo Injections and Luciferase Assay--
5' promoter deletion
and intron-2 fusion constructs were injected at 20 pg/blastomere into
two-cell stage embryos in both blastomeres or into four-cell stage
embryos in the dorsal or in the ventral blastomeres. When indicated,
RNA was co-injected into individual blastomeres. Embryos were collected
at stage 12.5 (staging according to Nieuwkoop and Faber (27)) and
frozen in liquid nitrogen. Embryos injected with luciferase reporter
constructs were processed as described previously (20).
Cycloheximide Treatment--
Embryos were injected at the
four-cell stage with indicated RNAs and grown until stage 7. Cycloheximide concentration for whole embryos was determined to be
sufficient at 30 µg/ml. Embryos were kept in cycloheximide until
control embryos had reached stage 10.5 and then fixed for in
situ whole mount hybridization.
Yeast Transcriptional Assay (28)--
Xvent-1 and Xvent-2 were
integrated in-frame into the BamHI recognition site of the
bacteria/yeast shuttle vector pAS2 (CLONTECH). Subsequently, the constructs have been transformed according to established procedures (yeast protocols handbook,
CLONTECH) into yeast strain Y187 employing
selection markers trp1 and leu2 (29) and plated on drop-out plates
missing tryptophan. Colonies were grown overnight in minimal medium in
the absence of tryptophan and the next day inoculated in YEPD medium.
Cells were harvested at 0.6 OD (600 nm), disintegrated, and assayed for
reporter gene activity by means of a colorimetric assay employing
ONPG
(o-nitrophenyl- -D-galactopyranoside) as a
substrate at 420 nm (30). The amount of expression was verified by
Western blot analysis due to a hemagglutinin A epitope tag provided by
pAS2 and by using mouse anti-HA monoclonal antibodies (Roche Molecular
Biochemicals). Visualization was performed with goat anti-mouse
antibodies using the ECL detection kit (Amersham Pharmacia Biotech).
Mobility Shift Assays and DNase I Footprinting--
The
isolation procedure of bacterially expressed Xvent-2 homeodomain
protein and the conditions for mobility shift and DNase I footprint
experiments are as described previously (31).
 |
RESULTS |
Activation of BMP-4 Expression in the Gastrula Stage
Embryo--
Since the related proteins BMP-2 and BMP-4 are known to
bind and activate the same receptors (32, 33), we first investigated whether the BMP-4 autoregulation in Xenopus might be
initiated by maternal BMP-2. Injection of BMP-2 RNA into the dorsal
blastomeres of four-cell stage embryos with subsequent in
situ whole mount hybridization for BMP-4 transcripts reveals
ectopic activation of BMP-4 in the most dorsal mesoderm, the dorsal lip
or Spemann organizer (Figs. 1,
A and B). In contrast, radial injection of the
truncated BMP type I receptor RNA leads, in a dose dependent response,
to an inhibition of BMP-4 transcription (Fig.
1C), thereby demonstrating that BMP signaling is required
for BMP-4 gene activation. Thus, the initial activation of
the BMP-4 autoregulatory loop could be triggered by endogenous BMP-2.
The BMP-2 gene is maternally transcribed and high levels of
transcripts are detected until the early gastrula stage (34, 35); BMP-2
protein is present at the late blastula/early gastrula stage (36,
37),2 when BMP-4
transcription is initiated.

View larger version (78K):
[in this window]
[in a new window]
|
Fig. 1.
Interaction of BMP-2, Xvent-2, and
GATA-2 with BMP-4. A-C, in situ whole mount
hybridizations demonstrate dorsal activation of BMP-4 after injection
of 400 pg of BMP-2 RNA into both dorsal blastomeres of four-cell stage
embryos or inhibition after radial injection of 500 pg of truncated BMP
receptor (tBR). D-F, BMP-4, Xvent-2, and Xvent-1
expression in CHX-treated embryos after injection of 400 pg of BMP-2
RNA. Note that CHX treatment prevents transcription of BMP-4
and Xvent-1 but not of Xvent-2. G and
J, dorsal injection of 600 pg of Xvent-2 RNA activates
BMP-4 transcription in dorsal mesoderm; this activation is
not observed with 500 pg of GATA-2 RNA. H and K,
Xvent-2 and GATA-2 expression in uninjected embryos and in embryos
after injection of BMP-2/4 RNA (400 pg) into both dorsal blastomeres of
four-cell stage embryos (I and L). Except for CHX
treatment all embryos are photographed with dorsal side
(top) and ventral side (bottom).
|
|
However, treatment of BMP-2 injected embryos with cycloheximide (CHX)
prior to midblastula transition prevents transcription of the
BMP-4 gene (Fig. 1D). As controls we used the
Xvent-2 gene (Fig. 1E) which is a direct target
for BMP signaling and the Xvent-1 gene (Fig. 1F)
which does not directly respond to BMP-2/4 (12). Thus it seems that the
autoregulatory loop is not direct but requires additional newly
synthesized proteins. Such factors should be activated by BMP-2/4
signaling and, in turn, up-regulate the BMP-4 gene. Xvent-1
was excluded, since it is neither directly activated by BMP-4 (Fig.
1F) nor is it able to activate BMP-4 (data not shown). To
investigate the role of Xvent-2 and GATA-2 on BMP-4 transcription, the corresponding RNAs were injected into dorsal blastomeres of four-cell stage embryos which were subsequently analyzed
for the presence of BMP-4 transcripts. Fig. 1, G and J, show that in case of Xvent-2 ventral and lateral
expression of BMP-4 is expanded and leads to circumferential expression
around the blastoporus, but not in the case of GATA-2. Vice versa,
dorsal injections of BMP-4 RNA or BMP-2 RNA lead to a strong increase of Xvent-2 or GATA-2, respectively (Fig. 1, I and
L). In conclusion, only Xvent-2, but not GATA-2, can be
regarded as potential activator of the BMP-4 gene and
might participate in the autocatalytic regulation of this gene.
Upstream and Intron Enhancers Regulate the BMP-4 Gene--
We have
previously shown by injection of promoter/reporter DNA constructs that
the Xenopus BMP-4 gene is activated by several enhancer
elements within the 5'-flanking region and within the second intron
(20). The upstream region between 206 and 156 responded to BMP
signaling, in that a 206/+54 mutant but not a 156/+54 mutant showed
a significant increase in reporter gene activity after co-injection
with BMP-4 RNA and a down-regulation following co-injection with
truncated BMP receptor RNA. Noteworthy, a mutant containing 116 nucleotides of the upstream region fused to complete intron-2 exhibited
higher reporter gene activity than approximately 5 kilobases of the
5'-flanking region. Thus, it is evident that intron-2 contains an
enhancer which significantly contributes to the activation of the
BMP-4 gene. Moreover, this mutant was stimulated by
co-injection with either BMP-4 or BMP-2 RNA, whereas co-injection with
chordin or truncated BMP receptor RNA led to a drastic decrease of
reporter gene activity.
By using serial deletion mutants we have now further delineated the
nucleotide element which contributes to the observed activity. Fig.
2A shows the deletion mutants
which have been used and a compilation of reporter activities generated
by various deletions of the upstream or intron regions after injection
into both blastomeres of two-cell stage embryos in the absence or
presence of co-injected BMP-2/4 RNA. While the 5' border of the BMP
responsive element within the upstream region was reduced to 20 bp
between positions 176 and 156 (Fig. 2B), major activity
of intron sequences was localized between positions +1815 and +1918
(Fig. 2C).

View larger version (27K):
[in this window]
[in a new window]
|
Fig. 2.
The 5'-flanking region and the second intron
of the Xenopus BMP-4 gene respond to BMP-2/4
signaling. A, genomic structure of the Xenopus
BMP-4 gene and schematic representation of mutants used for
luciferase reporter gene assays. All mutants are numbered according to
nucleotide position +1 of the transcription start site (indicated at
the first exon) and all contain a 116/+54 minimal promoter fragment
(shadowed) (additional mutants are described in Fig. 5).
Arrows indicate sites responding to Xvent-2. B,
DNA (20 pg) of upstream (B) or intron/reporter fusion
constructs (C) were co-injected with 200 pg of BMP-2 or
BMP-4 RNA, respectively, into both blastomeres of two-cell stage
embryos. Luciferase activity was measured when uninjected control
siblings had reached stage 12.5.
|
|
Xvent-2 as Mediator of BMP Signaling--
We next investigated
whether the observed stimulations by BMP-2/4 can also be obtained by
Xvent-2. Fig. 3A shows
reporter gene activities determined after co-injection of 5' flanking
and intron mutants with Xvent-2 RNA. Both the upstream and the intron mutants behaved similarly or even identically when co-injected with
BMP-4 or Xvent-2 RNA, respectively (compare with Fig. 2, B
and C). By using a 200-bp intron deletion mutant
(I-2 +1750/+1951) we observe a reduced basal activity and a loss of
stimulation both for BMP-2/4 (not shown) as well for Xvent-2 (Fig.
3A). These findings suggest that Xvent-2 serves as the
required component in mediating the autocatalytic regulation of the
BMP-4 gene. Additional support for this notion was rendered
by the finding that the +1815 mutant was strongly inhibited both by
chordin or a dominant negative Xvent-2 mutant (P40) (22), respectively,
but could be rescued in both cases by co-injection with wild type
Xvent-2 (Fig. 3B). Moreover, the activation obtained with
BMP-2 was drastically reduced by co-injection with the P40 mutant. This
negative interference supports the notion that Xvent-2 is required for
the activation of BMP-4, and it is consistent with the
observation that Xvent-2 (P40) inhibits BMP-4 transcription
in vivo (data not shown).

View larger version (22K):
[in this window]
[in a new window]
|
Fig. 3.
Xvent-2 mimics BMP-2/4 signaling effects on
the BMP-4 promoter. A, co-injection of
500 pg of Xvent-2 RNA stimulates both the individual upstream and
intron mutants at a similar extent as observed with BMP-2/4 RNA (see
Fig. 2B). B and C, while co-injections
of the +1815 (B) or +1738/+1969 intron mutant (C)
with 400 pg of Xvent-2 yield more than 2-fold increase of reporter
activity, 400 pg of Xvent-1 has no effect. Co-injection of 1 ng of
Xvent-2 (P40) or 1 ng of chordin RNA leads for both of these mutants to
a significant decrease of reporter activity, which can be rescued by
400 pg of Xvent-2 RNA. Note also, that the activation obtained with 300 pg of BMP-2 RNA is strongly inhibited by co-injection with 1.3 ng of
Xvent-2 (P40) RNA.
|
|
The activation observed with Xvent-2 is specific as it was never
observed with Xvent-1. This result does not agree with previous studies
using the Xvent-1 related PV.1 (21) but is consistent with the finding
that only Xvent-2, but not Xvent-1, is able to activate
BMP-4 transcription (38). An intron mutant comprising only
232 nucleotides (+1738 to +1969), but including the BMP response element, behaved similarly, in that it was activated by Xvent-2 and
inhibited by chordin or Xvent-2 (P40), respectively (Fig. 3C). In conclusion, these results are consistent with
Xvent-2 as a mediator of BMP signaling on the 176/ 156 upstream and
+1815/+1951 intron regions.
Xvent-2 Interacts with a BMP-4 Gene Enhancer--
To test whether
the biological effects observed upon co-injection of deletion mutants
with Xvent-2 RNA reflect direct binding of this homeobox protein to DNA
we have performed gel retardation assays and DNase I footprint analyses
with the Xvent-2 homeodomain. While bacterially expressed Xvent-2
homeodomain readily shifts the intron 2 region which had been shown to
elicit a biological response (Fig.
4A), we repeatedly failed to
demonstrate such an behavior with the corresponding upstream region
(data not shown). This result can be explained by the assumption that
an additional factor which might be synthesized under control of BMP
signaling via Xvent-2 is binding to this region.

View larger version (45K):
[in this window]
[in a new window]
|
Fig. 4.
DNA/protein interactions. A,
gel mobility shifts were performed with the bacterially expressed
Xvent-2 homeodomain (HD) on the +1738/+1969 intron target
sequence. 1, lane 1 contains free DNA;
lanes 2-4 contain increasing amounts (6.25, 12.5, and 25 ng) of Xvent-2 HD. 2, addition of increasing amounts of
unlabeled target sequence (specific inhibitor) leads to a loss of shift
of the labeled target. 3, addition of an unspecific
competitor ( 69/+54 DNA fragment) does not prevent shifting.
B, DNase I footprint of Xvent-2 HD was carried out for both
strands on the +1738/+1969 intron 2 fragment. Lane 1 shows
the A/G chemical sequencing reaction, lane 2 contains DNase
I-digested free DNA. Increasing amounts (25, 75, and 225 ng) of Xvent-2
HD were added prior to DNase I digestion in lanes 3-5.
Protected regions (indicated by lines) correspond for both
strands and contain two copies of the motif 5'-CTAATT-3'
(underlined). Gene sequence is shown from nucleotide
positions +1820 to + 1879. C, best fit alignment of the
X. laevis Xvent-2-binding site with the human and mouse
BMP-4 gene (number of matches: 13; allowed mismatches: 1).
Note that a 13-bp match (including one T to C transition) is found
within the proximal promoter of both the human (accession number
U43842) and the mouse BMP-4 genes (accession number
L47480).
|
|
Fig. 4B shows a DNase I footprint of the Xvent-2 homeodomain
protein on both strands of the intron 2 region, for which we could
demonstrate a stimulation upon Xvent-2 co-injection and band
retardation. The protected region corresponds for both strands and
contains two copies of a motif 5'-CTAATT-3'. This binding site defines
an AT-rich homeobox target sequence and it is rather similar to the
5'-CTATTT-3' motif we have previously shown to bind to Xvent-1 (31).
Even more important, this motif is fully compatible to the recently
published Xom (Xvent-2) target sequence derived from random
oligonucleotides by PCR selection (24) revealing two copies of a
TAAT/ATTA motif separated by six or seven nucleotides and the first
copy most frequently being found as 5'-CTAATT-3'. In the case of the
BMP-4 enhancer, the distance was found to be six
nucleotides, but the core motif 5'-CTAATT-3' is two times directly
repeated, whereas the PCR approach is reported to yield in 75% of
investigated sequences in antiparallel orientation. Search for this
element in the human and mouse BMP-4 genes (39-42), which
contain 5 instead of 3 exons, revealed the existence of a conserved
13-bp element within the proximal promoter region (Fig. 4C).
This region has also been implicated in transcriptional activation (40,
42). However, mammalian orthologues to Xvent-2 have so far not been
isolated; thus, it remains an open question whether these sites are
necessary in mammals and whether they bind to similar or other
homeodomain proteins.
The Core Enhancer is Required for Binding but Not Sufficient for
Activation--
We have further delineated the enhancer by additional
5' and 3' deletions to a 62-bp fragment extending from nucleotide
positions +1823 to +1884. This fragment is shifted by the Xvent-2
homeodomain and, after fusion to the 116/+54 basal promoter, results
in a distinct increase of reporter gene activity upon co-injection of
Xvent-2 (Fig. 5). Thus, all molecular and
biological data suggest that this region contributes to the activation
and autocatalytic regulation of the BMP-4 gene. Accordingly,
deletion of the two core motifs (+1842 to +1857) led to a loss of
binding, to reduced basal activity, and loss of stimulation by Xvent-2.
Interestingly, dissection of the 62-bp fragment into a 5' fragment (28 bp: +1823/+1850) and a 3' fragment (33 bp: +1852/+1884) revealed that,
while both fragments contain a core motif and still bind to the Xvent-2
homeodomain, only the 5' fragment responds to co-injection of Xvent-2.
These findings demonstrate a necessity of 5'-flanking nucleotides for transcriptional activation and that the core motif is required for
Xvent-2 binding but not sufficient to up-regulate the BMP-4 gene.

View larger version (28K):
[in this window]
[in a new window]
|
Fig. 5.
Delineation of Xvent-2 responsive
region. A and B, double stranded
oligonucleotides (5' elongated by a KpnI (forward) or a
XhoI (reverse) site) comprising positions +1823 to +1884
(1), +1823 to +1850 (2), +1852 to +1884
(3), and +1823/+1884 deleted from +1842 to +1857
(4) were subjected to gel mobility shifts with the Xvent-2
homeodomain as described in the legend to Fig. 4. Note that there is no
shift when both copies of the core motif (underlined) are
deleted but that one copy is sufficient for binding. C,
fragments were subcloned in front of the 116/+54 basal
BMP-4 promoter fused to the luciferase reporter. 20 pg of
DNA constructs were co-injected with 500 pg of Xvent-2 RNA into dorsal
blastomeres of four-cell stage embryos. Reporter activity of the
complete fragment is set as 100%. Note that neither the internal
deletion nor the 3' fragment containing one copy of the core motif can
be activated by Xvent-2.
|
|
Xvent-2 Serves as Transcriptional Activator--
Recent reports
demonstrated that constructs containing VP16 or GAL4 activation domains
(GAL4-AD) fused to Xvent-2 behave as antimorphs in acting as repressors
for ventral and as activators for dorsal genes (22-24). Accordingly,
Xvent-2 was postulated to serve as a repressor. To explain the
activation of ventral genes by Xvent-2, a mechanism was suggested
according to which Xvent-2 acting as a repressor inhibits transcription
of a yet unknown ventral suppressor.
Since these conclusions apparently contradict our present model for
Xvent-2 as an activator, we have prepared a GAL4-AD/Xvent-2 fusion
construct in pCS2 (23) to analyze the effect of microinjected RNA on
the BMP-4 gene promoter. Our results confirm the previous findings, but
the following experiments demonstrate that Xvent-2 has a dual role in
that it can also serve as transcriptional activator. First, all intron
deletion mutants lacking the Xvent-2 responding region show a reduced
activity as compared with the wild type sequence which is not
compatible with a suppressor model. Second, while ventral injection of
GAL4-AD/Xvent-2 fusion construct leads to an already described
duplication of posterior axis (23), dorsal injection causes a loss of
anterior structures suggesting ventralizing activity (Fig.
6A). Third, co-injection of
GAL4-AD/Xvent-2 at low concentration with the intron-2/reporter mutant
leads to a stimulation of reporter activity, whereas, at higher
concentration, an inhibition is observed (Fig. 6B). Fourth,
this concentration dependent dual effect can also be observed for the
wild type BMP-4 gene. In situ hybridizations show
that low concentrations lead to a weak but distinct activation at the
dorsal side, while high concentrations applied to the ventral side even
lead to clearance of BMP-4 transcripts (data not shown). Thus, at least
at low concentrations, this construct behaves as an activator of
BMP-4 gene transcription. Fifth, the difference between
Xvent-2 and Xvent-1 regarding their activatory potential was finally
also demonstrated in the yeast GAL4 assay (28). Fusions of the two
proteins to the GAL4 DNA-binding domain revealed that Xvent-2, but not
Xvent-1, like the GAL4 activation domain is a very potent activator of
the LacZ reporter gene (Fig. 6C). This result is not simply
due to a lower concentration of Xvent-1 fusion protein as demonstrated
by immunoblotting using a monoclonal hemagglutinin antibody. In
summary, all these results support the notion that Xvent-2, besides its
known suppressor function, can also act as a transcriptional
activator.

View larger version (53K):
[in this window]
[in a new window]
|
Fig. 6.
Repressing and activating functions of
Xvent-2. A, phenotypes of embryos (around st. 30)
injected ventrally (a, b) or dorsally (c, d) with
1.5 ng of GAL4-AD/Xvent-2 RNA perblastomere at the four-cell stage.
Note formation of a posterior double axis (arrowhead) at
ventral and ventralization at dorsal injections. The inset
in a shows an uninjected control embryo (all embryos are
orientated with posterior to left and anterior to right). B,
an intron 2/basal BMP-4 promoter/luciferase reporter
construct is activated by co-injection with low amounts of
GAL4-AD/Xvent-2 RNA into dorsal blastomeres of four-cell stage embryos.
Higher amounts lead to reversal or even to inhibition, as shown by
ventral co-injection with 1.5 ng of perblastomere. C, a
yeast-based assay was used to determine the transactivatory efficiency
of Xvent-1 and Xvent-2. Complete proteins were fused to the GAL4
DNA-binding domain and expressed in pAS2 under control of the ADH
promoter. The recombinants were transfected into yeast strain Y187,
thereby prompting an interaction between the GAL4 fusions and the
genomic GAL1-binding site giving rise to the activation of the LacZ
reporter. Efficiency of fusion protein synthesis was controlled by
immunoblotting of yeast extracts using monoclonal hemagglutinin
antibodies. The enzymatic activity of LacZ was determined after
1 h in arbitrary units relative to the activatory strength of the
GAL-4 activation domain.
|
|
Activation of the Goosecoid Promoter by the BMP-4 Intron
Enhancer--
It has recently been shown that dorsal activity of the
goosecoid (gsc) gene is repressed by Xom
(Xvent-2) and that Xom as transcriptional repressor directly interacts
with several target sites located between 128 to 226 on the
gsc promoter (24). Since Xvent-2 in the case of the
BMP-4 gene acts as transcriptional activator, we have asked
whether distinct features of the binding region or the basal promoters
are responsible for this differential behavior. The corresponding
region of the gsc promoter was replaced by the intron
enhancer of the BMP-4 gene and, vice versa, the Xvent-2-binding region of the gsc promoter was fused to the
basal BMP promoter. These constructs were co-injected with
Xvent-2 into dorsal blastomeres of four-cell stage embryos.
Fig. 7 demonstrates that the
BMP-4 intron enhancer converts Xvent-2 which caused
repression of gsc promoter activity to strong activation,
whereas the Xvent-2 binding region of gsc leads to an
inhibition of the basal BMP-4 promoter. These results
convincingly demonstrate the dual role of Xvent-2 as repressor and
activator and they render additional evidence that nucleotide motifs
adjacent to the core target sites of Xvent-2 determine the mode of
regulation. Alternatively, the direct orientation of two core motifs
within the intron enhancer instead of antiparallel orientation within the gsc promoter region could explain this differential
behavior; however, we estimate this assumption to be less likely,
because we observed stimulation already with only one copy of the core motif of the intron enhancer including its 5'-flanking region (see Fig.
5).

View larger version (11K):
[in this window]
[in a new window]
|
Fig. 7.
BMP-4/goosecoid promoter
swapping. The goosecoid promoter has recently been
shown to contain several Xom (Xvent-2)-binding sites (BS)
located between 128 and 226, thereby mediating Xvent-2 caused
repression of activin A-stimulated promoter/reporter activity (24). In
contrast, the intron 2 enhancer (+1815/+1892) fused to the basal
BMP-4 promoter yields a strong activation upon co-injection
of Xvent-2. Promoter swapping of corresponding gsc and
intron 2 enhancer regions reveals that not the basal promoters, but
that the Xvent-2-binding sites are responsible for repression or
activation, depending on the context. Reporter activities determined
after injection of 20 pg of DNA constructs into dorsal blastomeres at
the four-cell stage are set as 100%, the values obtained upon
co-injection of 500 pg of Xvent-2 RNA are given as relative
percentage.
|
|
Xvent-2 Requires a Co-factor for Transcriptional Activation of the
BMP-4 Gene--
The experimental results suggest that the activatory
function of Xvent-2 is context-dependent and requires
additional sequence motifs which probably bind to a co-activator. If
this hypothesis holds true, we would expect that the Xvent-2 function
by itself is not sufficient to up-regulate BMP-4 expression.
We therefore have analyzed the ability of Xvent-2 to activate
BMP-4 gene transcription in the presence of CHX. RT-PCR of
RNA from Xvent-2-injected embryos and from uninjected control embryos
grown in the absence or presence of CHX (Fig.
8) as well as an in situ whole
mount hybridization of corresponding embryos (data not shown) clearly
demonstrate that CHX, in contrast to untreated embryos, significantly
diminishes or even prevents BMP-4 transcription. This result
allows the conclusion that activation of BMP-4 by Xvent-2
requires a co-activator which is either de novo synthesized
or whose recruitment is blocked by treatment with CHX. An alternative
could be that Xvent-2 directs synthesis of another homeodomain
transcription factor which binds to the same AT-rich motif as found for
Xvent-2. However, the demonstrated binding of Xvent-2 to the BMP-4
intron enhancer makes such a hypothesis less likely, but certainly does
not rule out binding of other related factors.

View larger version (41K):
[in this window]
[in a new window]
|
Fig. 8.
Cycloheximide treatment subsequent to Xvent-2
overexpression prevents BMP-4 gene activation.
A, four-cell stage embryos were injected with 400 pg of
Xvent-2 RNA into both dorsal blastomeres. Cycloheximide treatment was
performed as described under "Experimental Procedures." RT-PCR was
performed with total RNA for BMP-4 (upstream primer:
5'-GATTGGCTGTCAAGAATCATGGA-3'; downstream primer 5':
GAACATCTGCAGCAGCGTCACCTCG-3') and had been adjusted using histone H4
(upstream primer: 5'-CGGGATAACATTCAGGGTATCACT-3'; downstream primer:
5'-ATCCATGGCGGTAACTGTCTTCCT-3') as an internal control.
|
|
 |
DISCUSSION |
We here show that zygotic activation of the BMP-4 gene
at late blastula/early gastrula stage can be triggered by BMP-2 which, in vivo, is translated from maternal transcripts being
present until the gastrula stage within the embryo (35). In addition, maternal BMP-4 transcripts being present at a very low level (34, 43)
could also be translated during early cleavage stages and contribute to
zygotic activation of the gene. In line with this, injection of
truncated BMP receptor prevents formation of BMP-4 transcripts at the gastrula stage. Thus it is likely that BMP signaling
is a major component not only in the maintenance but also in the
activation of the Xenopus BMP-4 gene. Similar conclusions can be drawn from zebrafish mutants. At least the maintenance of zBMP-2
and zBMP-4 is affected in swirl (zBMP-2) mutant embryos; zBMP-4 expression in the ventral marginal region depends on zBMP-2 as
indicated by the reduced initial expression and subsequent loss of the
marginal zone zBMP-4 expression in swirl mutant embryos (44). Also, the
requirement of BMP signal transducers has been documented. BMP2b and
Smad5 (somitabun: sbn) double mutant analysis and
RNA injection experiments have shown that sbn acts
downstream of BMP2b signaling to mediate BMP2b autoregulation during
early dorsoventral pattern formation (45).
However, cycloheximide treatment of BMP-2-injected Xenopus
embryos prior to midblastula transition prevents BMP-4
transcription; thus it seems clear that the activation and/or the
autoregulatory loop are not direct but indirect. As putative mediators
we have investigated several genes which are activated by BMP-2/4. In turn, corresponding proteins should also be able to activate the BMP-4 gene when overexpressed within the embryo. We found
that Xvent-2, but not Xvent-1, GATA-2, or Xwnt-8 (46)2
fulfill both of these requirements. Therefore, the results suggest that
Xvent-2 might be directly involved in the transcriptional regulation of
the BMP-4 gene. Also, the activatory potential of Xvent-2
for BMP-4 as well as for Xvent-1 transcription
(12) strongly suggests that Xvent-2 does not only work as a repressor as recently suggested (22-24), but additionally serves as a
transcriptional activator. We here demonstrate that the GAL4 activator
domain/Xvent-2 fusion protein behaves for the BMP-4 promoter
in a dose-dependent manner as a transcriptional activator
which then is converted to a repressor at higher concentrations. The
inhibition of ventral genes observed after injection at high
concentrations might be explained by an artificial activation of dorsal
genes, like goosecoid and chordin, which are
known to suppress ventral genes. Also, a comparison of the activatory
potential of Xvent-1 to that of Xvent-2 in the yeast system clearly
indicates that Xvent-2, in contrast to Xvent-1, behaves as an
activator. Finally, swapping of the BMP-4 intron enhancer to
the gsc promoter converts Xvent-2 from acting as a repressor
to a transcriptional activator. However, the activatory potential of
Xvent-2 on BMP-4 gene transcription requires an additional
co-activator, because CHX treatment prevents activation. A search for
this co-activator is under current investigation. The results obtained
from the present and previous works (12, 24, 31, 47) can be summarized
in a scheme as shown in Fig. 9.
Accordingly, BMP-2 triggers the BMP signaling pathway at the early
gastrula stage by directly activating Xvent-2. Xvent-2, together with a transcriptional co-activator, activates
BMP-4 and, as recently shown, Xvent-2 suppresses
goosecoid; both, Xvent-2 and GATA-2 activate
Xvent-1 which serves as a transcriptional repressor for the
dorsal lip specific fork head gene XFD-1'.

View larger version (29K):
[in this window]
[in a new window]
|
Fig. 9.
Genetic cascades involved in the activation
and autocatalytic regulation of BMP-4. While BMP-4 activates
Xvent-2 and GATA-2, only Xvent-2 is able to
up-regulate BMP-4. BMP-2 protein translated from maternal
RNA activates Xvent-2 and triggers the autocatalytic loop,
which is subsequently maintained by BMP-4 and Xvent-2 recruiting a yet
unknown co-activator. Xvent-2 suppresses gsc. GATA-2 and
Xvent-2 activate Xvent-1 which has been shown to repress
ventral expression of the dorsal lip-specific winged helix gene
XFD-1' (12, 24, 31, 47).
|
|
Noteworthy, a comparison of the temporal expression of Xvent-2 (14)
versus that of BMP-4 (43, 48) also supports the notion that
Xvent-2 serves as a regulatory component for the zygotic activation of
BMP-4 gene transcription. Actually, Xvent-2
transcription clearly precedes that of BMP-4 and the spatial
pattern of Xvent-2 which is almost identical to that of BMP-4 is
consistent with its role in BMP-4 gene activation.
To localize enhancers on the BMP-4 promoter which interact
with factors being involved in the autoregulatory loop, we have investigated a series of deletion mutants from the 5'-flanking region
and the second intron fused to a luciferase reporter gene by
co-injection with BMP-2/4, chordin, Xvent-2, and dominant negative Xvent-2 (P40) RNA. The results demonstrate the existence of two sites,
one upstream and one in intron 2, responding to Xvent-2. Comparing
reporter gene activities obtained by co-injection with BMP-2/4 to those
obtained with Xvent-2 we find a correlation for all mutants tested
regarding their potential and their extent of stimulation. Thus, on a
qualitative and a quantitative level, Xvent-2 mimics the action of
BMP-2/4 and seems to be the major player in the autocatalytic loop.
Also, down-regulation observed with chordin directly correlates to
BMP-2/4 reactive mutants and can be rescued by Xvent-2. This finding
supports our previous notion that transcriptional repression of
BMP-4 by chordin is solely due to chordin/BMP-4 interaction
at the protein level, thereby interfering with the autoregulatory loop
(20).
Finally, we have investigated the ability of Xvent-2 to interact with
DNA motifs found to be essential in reporter gene activation. We
demonstrate that the Xvent-2 responsive element in intron 2 is retarded
by the Xvent-2 homeodomain, but we failed in mobility shifts using the
upstream Xvent-2 responsive region. Thus, we have to conclude that the
action of Xvent-2 on the upstream region is not direct but indirect and
requires the action of another, further downstream factor. The intron
target was subjected to DNase I footprinting. The result corresponds
for both strands and reveals a duplicated 5'-CTAATT-3' motif as a
target motif for Xvent-2. This strongly supports previous findings of a
Xom (Xvent-2) target consensus sequence derived by a PCR-based
oligonucleotide selection procedure containing exactly this motif (24).
The fact that the biological effects observed in reporter gene
activation assays coincide with the presence of this element strongly
supports the notion that this motif serves as a natural Xvent-2-binding site. Moreover, it displays a high degree of conservation to the 5'-CTATTT-3' motif, which we have recently described as a Xvent-1 target site within the XFD-1' promoter (31).
In summary, we show both for the wild type gene and for
promoter/reporter constructs that the autocatalytic regulation of the
BMP-4 gene is mediated by Xvent-2. Results obtained from
biological and molecular investigations are compatible with the notion
that the autoregulatory loop of BMP-4 is initially triggered by
maternal BMP-2 signals activating Xvent-2 and maintained during early
development by Xvent-2. The major contribution of intron 2 to
transcriptional activation of BMP-4 coincides with two
copies of a 5'-CTAATT-3' target motif which have the potential to bind
to Xvent-2. Although our results do definitely not rule out the
possibility that other factors being activated by BMP-4,
e.g. msx1 or Xvex-1 (49, 50), might participate in the
autocatalytic loop, we provide the first insight into the regulatory
mechanisms governing the transcription of the BMP-4 gene in
Xenopus embryos.
 |
ACKNOWLEDGEMENTS |
We gratefully acknowledge the skillful
technical assistance of K. Dillinger and D. Weber. We thank M. Köster for assistance in microinjections and H. Friedle for help
in cycloheximide experiments. We are indebted to C. Niehrs, Heidelberg,
for the Xvent-2 (P40) mutant and R. Patient, London, for GATA-2 cDNA.
 |
FOOTNOTES |
*
This work was supported by Deutsche Forschungsgemeinschaft
Grants Kn 200/4-6 and SFB 497/A1 and the Fonds der Chemischen
Industrie.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
Contributed equally to the results of this work.
§
To whom correspondence should be addressed. Tel.:
49-731-502-3280; Fax: 49-731-502-3277; E-mail:
walter.knoechel@medizin.uni-ulm.de.
Published, JBC Papers in Press, August 10, 2000, DOI 10.1074/jbc.M003915200
2
A. Schuler-Metz, S. Knöchel, E. Kaufmann,
and W. Knöchel, unpublished results.
 |
ABBREVIATIONS |
The abbreviations used are:
BMP, bone
morphogenetic protein;
RT-PCR, reverse transcriptase-polymerase chain
reaction;
CHX, cycloheximide;
bp, base pair(s).
 |
REFERENCES |
| 1.
|
Hogan, B. L. M.
(1996)
Genes Dev.
10,
1580-1594
|
| 2.
|
Graff, J. M.
(1997)
Cell
89,
171-174
|
| 3.
|
Huang, J.-D.,
Schwyter, D. H.,
Shirokawa, J. M.,
and Courey, A. J.
(1993)
Genes Dev.
7,
694-704
|
| 4.
|
Jackson, P. D.,
and Hoffmann, F. M.
(1994)
Dev. Dyn.
199,
28-44
|
| 5.
|
Schwyter, D. H.,
Huang, J.-D.,
Dubnicoff, T.,
and Courey, A. J.
(1995)
Mol. Cell. Biol.
15,
3960-3968
|
| 6.
|
Hursh, D. A.,
Padgett, R. W.,
and Gelbart, W. M.
(1993)
Development
117,
1211-1222
|
| 7.
|
Thüringer, F.,
and Bienz, M.
(1993)
Proc. Natl. Acad. Sci. U. S. A.
90,
3899-3903
|
| 8.
|
Riesgo-Escovar, J. R.,
and Hafen, E.
(1997)
Science
278,
669-672
|
| 9.
|
Kim, S.-J.,
Angel, P.,
Lafyatis, R.,
Hattori, K.,
Kim, K. Y.,
Sporn, M. B.,
Karin, M.,
and Roberts, A. B.
(1990)
Mol. Cell. Biol.
10,
1492-1497
|
| 10.
|
Jones, C. M.,
Lyons, K. M.,
Lapan, P. M.,
Wright, C. V. E.,
and Hogan, B. L. M.
(1992)
Development
115,
639-647
|
| 11.
|
Gawantka, V.,
Delius, H.,
Hirschfeld, K.,
Blumenstock, C.,
and Niehrs, C.
(1995)
EMBO J.
14,
6268-6279
|
| 12.
|
Rastegar, S.,
Friedle, H.,
Frommer, G.,
and Knöchel, W.
(1999)
Mech. Dev.
81,
139-149
|
| 13.
|
Ault, K. T.,
Dirksen, M.-L.,
and Jamrich, M.
(1996)
Proc. Natl. Acad. Sci. U. S. A.
93,
6415-6420
|
| 14.
|
Onichtchouk, D.,
Gawantka, V.,
Dosch, R.,
Delius, H.,
Hirschfeld, K.,
Blumenstock, C.,
and Niehrs, C.
(1996)
Development
122,
3045-3053
|
| 15.
|
Schmidt, J. E.,
von Dassow, G.,
and Kimelman, D.
(1996)
Development
122,
1711-1721
|
| 16.
|
Ladher, R.,
Mohun, T. J.,
Smith, J. C.,
and Snape, A. M.
(1996)
Development
122,
1769-1779
|
| 17.
|
Papalopulu, N.,
and Kintner, C.
(1996)
Dev. Biol.
174,
104-114
|
| 18.
|
Kelley, C.,
Yee, K.,
Harland, R.,
and Zon, L. I.
(1994)
Dev. Biol.
165,
193-205
|
| 19.
|
Maeno, M.,
Mead, P. E.,
Kelley, C.,
Xu, R.-H.,
Kung, H.-F.,
Suzuki, A.,
Ueno, N.,
and Zon, L. I.
(1996)
Blood
88,
1965-1972
|
| 20.
|
Metz, A.,
Knöchel, S.,
Büchler, P.,
Köster, M.,
and Knöchel, W.
(1998)
Mech. Dev.
74,
29-39
|
| 21.
|
Kim, J.,
Tidman Ault, K.,
Chen, H.-D.,
Xu, R.-H.,
Roh, D.-H.,
Lin, M. C.,
Park, M.-J.,
and Kung, H.-F.
(1998)
Biochem. Biophys. Res. Commun.
250,
516-530
|
| 22.
|
Onichtchouk, D.,
Glinka, A.,
and Niehrs, C.
(1998)
Development
125,
1447-1456
|
| 23.
|
Melby, A. E.,
Clements, W. K.,
and Kimelman, D.
(1999)
Dev. Biol.
211,
293-305
|
| 24.
|
Trindade, M.,
Tada, M.,
and Smith, J. C.
(1999)
Dev. Biol.
216,
442-456
|
| 25.
|
Fainsod, A.,
Steinbeisser, H.,
and De Robertis, E. M.
(1994)
EMBO J.
13,
5015-5025
|
| 26.
|
Harland, R. M.
(1991)
in
Methods in Cell Biology
(Kay, B. K.
, and Peng, H. B., eds)
, pp. 685-695, Academic Press, San Diego, CA
|
| 27.
|
Nieuwkoop, P. D.,
and Faber, J.
(1975)
Normal Table of Xenopus laevis (Daudin)
, North Holland Publishing Co., Amsterdam
|
| 28.
|
Mardon, G.,
Luoh, S. W.,
Simpson, E. M.,
Gill, G.,
Brown, L. G.,
and Page, D. C.
(1990)
Mol. Cell. Biol.
10,
681-688
|
| 29.
|
Harper, J. W.,
Adami, G. R.,
Wei, N.,
Keyomarsi, K.,
and Elledge, S. J.
(1993)
Cell
75,
805-816
|
| 30.
|
Guarente, L.
(1983)
Methods Enzymol.
101,
181-184
|
| 31.
|
Friedle, H.,
Rastegar, S.,
Paul, H.,
Kaufmann, E.,
and Knöchel, W.
(1998)
EMBO J.
17,
2298-2307
|
| 32.
|
Yamaji, N.,
Celeste, A. J.,
Thies, R. S.,
Song, J. J.,
Bernier, S. M.,
Goltzman, D.,
Lyons, K. M.,
Nove, J.,
Rosen, V.,
and Wozney, J. M.
(1994)
Biochem. Biophys. Res. Commun.
205,
1944-1951
|
| 33.
|
Massagué, J.
(1998)
Annu. Rev. Biochem.
67,
753-791
|
| 34.
|
Nishimatsu, S.,
Suzuki, A.,
Shoda, A.,
Murakami, K.,
and Ueno, N.
(1992)
Biochem. Biophys. Res. Commun.
186,
1487-1495
|
| 35.
|
Clement, J. H.,
Fettes, P.,
Knöchel, S.,
Lef, J.,
and Knöchel, W.
(1995)
Mech. Dev.
52,
357-370
|
| 36.
|
Ueno, N.,
Shoda, A.,
Takebayashi, K.,
Suzuki, A.,
Nishimatsu, S.-I.,
Kikuchi, T.,
Wakimasu, M.,
Fujino, M.,
and Murakami, K.
(1992)
Growth Factors
7,
233-240
|
| 37.
|
Shoda, A.,
Murakami, K.,
and Ueno, N.
(1993)
Growth Factors
8,
165-172
|
| 38.
|
Lemaire, P.
(1996)
Bioassays
18,
701-704
|
| 39.
|
Kurihara, T.,
Kitamura, K.,
Takaoka, K.,
and Nakazato, H.
(1993)
Biochem. Biophys. Res. Commun.
192,
1049-1056
|
| 40.
|
Feng, J. Q.,
Chen, D.,
Cooney, A. J.,
Tsai, M.-J.,
Harris, M. A.,
Tsai, S. Y.,
Feng, M.,
Mundy, G. R.,
and Harris, S. E.
(1995)
J. Biol. Chem.
270,
28364-28373
|
| 41.
|
van den Wijngaard, A.,
van Kraay, M.,
van Zoelen, E. J. J.,
Olijve, W.,
and Boersma, C. J. C.
(1996)
Biochem. Biophys. Res. Commun.
219,
789-794
|
| 42.
|
Shore, E. M.,
Xu, M.,
Shah, P. B.,
Janoff, H. B.,
Hahn, G. V.,
Deardorff, M. A.,
Sovinsky, L.,
Spinner, N. B.,
Zasloff, M. A.,
Wozney, J. M.,
and Kaplan, F. S.
(1998)
Calcif. Tissue Int.
63,
221-229
|
| 43.
|
Köster, M.,
Plessow, S.,
Clement, J. H.,
Lorenz, A.,
Tiedemann, H.,
and Knöchel, W.
(1991)
Mech. Dev.
33,
191-200
|
| 44.
|
Kishimoto, Y.,
Lee, K.-H.,
Zon, L.,
Hammerschmidt, M.,
and Schulte-Merker, S.
(1997)
Development
124,
4457-4466
|
| 45.
|
Hild, M.,
Dick, A.,
Rauch, G.-J.,
Meier, A.,
Bouwmeester, T.,
Haffter, P.,
and Hammerschmidt, M.
(1999)
Development
126,
2149-2159
|
| 46.
|
Hoppler, S.,
and Moon, R. T.
(1998)
Mech. Dev.
71,
119-129
|
| 47.
|
Sykes, T. G.,
Rodaway, A. R. F.,
Walmsley, M. E.,
and Patient, R. K.
(1998)
Development
125,
4595-4605
|
| 48.
|
Dale, L.,
Howes, G.,
Price, B. M. J.,
and Smith, J. C.
(1992)
Development
115,
573-585
|
| 49.
|
Suzuki, A.,
Ueno, N.,
and Hemmati-Brivanlou, A.
(1997)
Development
124,
3037-3044
|
| 50.
|
Shapira, E.,
Marom, K.,
Levy, V.,
Yelin, R.,
and Fainsod, A.
(2000)
Mech. Dev.
90,
77-87
|
Copyright © 2000 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
T. Oren, I. Torregroza, and T. Evans
An Oct-1 binding site mediates activation of the gata2 promoter by BMP signaling
Nucleic Acids Res.,
August 1, 2005;
33(13):
4357 - 4367.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. Cao, S. Knochel, C. Donow, J. Miethe, E. Kaufmann, and W. Knochel
The POU Factor Oct-25 Regulates the Xvent-2B Gene and Counteracts Terminal Differentiation in Xenopus Embryos
J. Biol. Chem.,
October 15, 2004;
279(42):
43735 - 43743.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. J. Sadlon, I. D. Lewis, and R. J. D'Andrea
BMP4: Its Role in Development of the Hematopoietic System and Potential as a Hematopoietic Growth Factor
Stem Cells,
July 1, 2004;
22(4):
457 - 474.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. Martynova, F. Eroshkin, G. Ermakova, A. Bayramov, J. Gray, R. Grainger, and A. Zaraisky
Patterning the forebrain: FoxA4a/Pintallavis and Xvent2 determine the posterior limit of Xanf1 expression in the neural plate
Development,
May 15, 2004;
131(10):
2329 - 2338.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. M. Ward, J. S. Desgrosellier, X. Zhuang, J. V. Barnett, and J. B. Galper
Transforming Growth Factor beta (TGFbeta ) Signaling via Differential Activation of Activin Receptor-like Kinases 2 and 5 during Cardiac Development. ROLE IN REGULATING PARASYMPATHETIC RESPONSIVENESS
J. Biol. Chem.,
December 13, 2002;
277(51):
50183 - 50189.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. Friedle and W. Knochel
Cooperative Interaction of Xvent-2 and GATA-2 in the Activation of the Ventral Homeobox Gene Xvent-1B
J. Biol. Chem.,
June 21, 2002;
277(26):
23872 - 23881.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. Imai, M. A. Gates, A. E. Melby, D. Kimelman, A. F. Schier, and W. S. Talbot
The homeobox genes vox and vent are redundant repressors of dorsal fates in zebrafish
Development,
June 15, 2001;
128(12):
2407 - 2420.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. A. Henningfeld, H. Friedle, S. Rastegar, and W. Knochel
Autoregulation of Xvent-2B; Direct Interaction and Functional Cooperation of Xvent-2 and Smad1
J. Biol. Chem.,
January 11, 2002;
277(3):
2097 - 2103.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2000 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|